BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 13, 2010
 |  BioCentury  |  Emerging Company Profile

Delenex: Fragments, Take Two

ESBATech syndicate double dipping with Delenex antibody fragments spinout

Investors in Delenex Therapeutics AG are looking for a second ROI from a technology platform that's already provided them with one exit after 11 years and $72 million in investment. The company is a spinout from ESBATech AG and thus starting out with a fully developed antibody fragment platform technology and a lead candidate that's already shown proof of concept, albeit in a different indication.

ESBATech was founded in 1998 and was sold along with its ophthalmic assets to Alcon Inc. in 2009 for $150 million in cash and up to $439 million in undisclosed milestones (see Ebb & Flow, Sept. 21, 2009).

Following the deal, the investors spun out Delenex with exclusive rights to ESBATech's PENTRA antibody fragment technology for diseases outside of ophthalmology. The company is focusing...

Read the full 638 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >